Cargando…
Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea
OBJECTIVE: To investigate the current status of pharmacotherapy prescribed by physiatrists in Korea for cognitive-behavioral disorder. METHODS: A cross-sectional study was performed by mailing questionnaires to 289 physiatrists working at teaching hospitals. Items on the questionnaire evaluated pres...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Academy of Rehabilitation Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852227/ https://www.ncbi.nlm.nih.gov/pubmed/29560322 http://dx.doi.org/10.5535/arm.2018.42.1.35 |
_version_ | 1783306528448577536 |
---|---|
author | Huh, Sungchul Kim, Tae Wan Yang, Jung Hyun Moon, Myung Hoon Kim, Soo-Yeon Ko, Hyun-Yoon |
author_facet | Huh, Sungchul Kim, Tae Wan Yang, Jung Hyun Moon, Myung Hoon Kim, Soo-Yeon Ko, Hyun-Yoon |
author_sort | Huh, Sungchul |
collection | PubMed |
description | OBJECTIVE: To investigate the current status of pharmacotherapy prescribed by physiatrists in Korea for cognitive-behavioral disorder. METHODS: A cross-sectional study was performed by mailing questionnaires to 289 physiatrists working at teaching hospitals. Items on the questionnaire evaluated prescribing patterns of 16 drugs related to cognitive-behavioral therapy, the status of combination pharmacotherapy, and tools for assessing target symptoms. RESULTS: Fifty physiatrists (17.3%) including 24 (48%) specializing in neurorehabilitation completed the questionnaires. The most common target symptom was attention deficit (29.5%). Donepezil and methylphenidate (96.0%) were the most frequently prescribed drugs for cognitive-behavioral improvement. Mostly, a combination of two drugs was prescribed (38.0%), and the most common combination therapy included donepezil plus methylphenidate (19.1%). Pharmacotherapy for cognitive-behavioral disorder after brain injury was typically initiated within 2 months (69.5%). A follow-up assessment was usually performed at 1 month after treatment initiation (31.0%). The most common reason for treatment discontinuation was improvement of target symptoms (37.8%). The duration of pharmacotherapy was 3–12 months (57.7%), 1–2 years (17.9%), or 1–2 months (13.6%). CONCLUSION: According to the survey, combination pharmacotherapy is preferred to monotherapy for the treatment of cognitive-behavioral disorder in patients with brain injury. Physiatrists expressed diverse views on the definition of target symptoms, prescribing patterns, and the status of drug combination therapy. Guidelines are needed for cognitive-behavioral pharmacotherapy. Further research should investigate drug costs and aim to reduce polypharmacy and adverse drug reactions. |
format | Online Article Text |
id | pubmed-5852227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Korean Academy of Rehabilitation Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-58522272018-03-20 Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea Huh, Sungchul Kim, Tae Wan Yang, Jung Hyun Moon, Myung Hoon Kim, Soo-Yeon Ko, Hyun-Yoon Ann Rehabil Med Original Article OBJECTIVE: To investigate the current status of pharmacotherapy prescribed by physiatrists in Korea for cognitive-behavioral disorder. METHODS: A cross-sectional study was performed by mailing questionnaires to 289 physiatrists working at teaching hospitals. Items on the questionnaire evaluated prescribing patterns of 16 drugs related to cognitive-behavioral therapy, the status of combination pharmacotherapy, and tools for assessing target symptoms. RESULTS: Fifty physiatrists (17.3%) including 24 (48%) specializing in neurorehabilitation completed the questionnaires. The most common target symptom was attention deficit (29.5%). Donepezil and methylphenidate (96.0%) were the most frequently prescribed drugs for cognitive-behavioral improvement. Mostly, a combination of two drugs was prescribed (38.0%), and the most common combination therapy included donepezil plus methylphenidate (19.1%). Pharmacotherapy for cognitive-behavioral disorder after brain injury was typically initiated within 2 months (69.5%). A follow-up assessment was usually performed at 1 month after treatment initiation (31.0%). The most common reason for treatment discontinuation was improvement of target symptoms (37.8%). The duration of pharmacotherapy was 3–12 months (57.7%), 1–2 years (17.9%), or 1–2 months (13.6%). CONCLUSION: According to the survey, combination pharmacotherapy is preferred to monotherapy for the treatment of cognitive-behavioral disorder in patients with brain injury. Physiatrists expressed diverse views on the definition of target symptoms, prescribing patterns, and the status of drug combination therapy. Guidelines are needed for cognitive-behavioral pharmacotherapy. Further research should investigate drug costs and aim to reduce polypharmacy and adverse drug reactions. Korean Academy of Rehabilitation Medicine 2018-02 2018-02-28 /pmc/articles/PMC5852227/ /pubmed/29560322 http://dx.doi.org/10.5535/arm.2018.42.1.35 Text en Copyright © 2018 by Korean Academy of Rehabilitation Medicine http://creativecommons.org/licenses/by-nc/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Huh, Sungchul Kim, Tae Wan Yang, Jung Hyun Moon, Myung Hoon Kim, Soo-Yeon Ko, Hyun-Yoon Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea |
title | Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea |
title_full | Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea |
title_fullStr | Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea |
title_full_unstemmed | Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea |
title_short | Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea |
title_sort | pharmacotherapy prescription trends for cognitive-behavioral disorder in patients with brain injury in korea |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852227/ https://www.ncbi.nlm.nih.gov/pubmed/29560322 http://dx.doi.org/10.5535/arm.2018.42.1.35 |
work_keys_str_mv | AT huhsungchul pharmacotherapyprescriptiontrendsforcognitivebehavioraldisorderinpatientswithbraininjuryinkorea AT kimtaewan pharmacotherapyprescriptiontrendsforcognitivebehavioraldisorderinpatientswithbraininjuryinkorea AT yangjunghyun pharmacotherapyprescriptiontrendsforcognitivebehavioraldisorderinpatientswithbraininjuryinkorea AT moonmyunghoon pharmacotherapyprescriptiontrendsforcognitivebehavioraldisorderinpatientswithbraininjuryinkorea AT kimsooyeon pharmacotherapyprescriptiontrendsforcognitivebehavioraldisorderinpatientswithbraininjuryinkorea AT kohyunyoon pharmacotherapyprescriptiontrendsforcognitivebehavioraldisorderinpatientswithbraininjuryinkorea |